Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P08908 (
5-HT1A
)
5,574
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Abnormal serotonin type 1A (
5-HT1A
) receptor function and binding have been implicated in the pathophysiology of mood disorders. Preclinical studies have consistently shown that stress decreases the gene expression of
5-HT1A
receptors in experimental animals, and that the associated increase in hormone secretion plays a crucial role in mediating this effect. Chronic administration of the mood stabilizers lithium and divalproex (valproate semisodium) reduces glucocorticoid signaling and function in the hippocampus. Lithium has further been shown to enhance
5-HT1A
receptor function. To assess whether these effects translate to human subject with bipolar disorder (BD), positron emission tomography (PET) and [18F]trans-4-fluoro-N-(2-[4-(2-methoxyphenyl) piperazino]-ethyl)-N-(2-pyridyl) cyclohexanecarboxamide ([(18)F]FCWAY) were used to acquire PET images of
5-HT1A
receptor binding in 10 subjects with BD, before and after treatment with lithium or divalproex. Mean
5-HT1A
binding potential (
BPP
) significantly increased following mood stabilizer treatment, most prominently in the mesiotemporal cortex (hippocampus plus amygdala). When mood state was also controlled for, treatment was associated with increases in
BPP
in widespread cortical areas. These preliminary findings are consistent with the hypothesis that these mood stabilizers enhance
5-HT1A
receptor expression in BD, which may underscore an important component of these agents' mechanism of action.
...
PMID:Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression. 2392 39
Neuroticism is a personality trait associated with vulnerability for mood and anxiety disorders. Serotonergic mechanisms likely contribute to neuroticism. Serotonin
5-HT1A
receptors are altered in mood and anxiety disorders, but whether
5-HT1A
receptors are associated with neuroticism in healthy subjects is unclear. We measured brain serotonin
5-HT1A
receptor in 34 healthy subjects in vivo using positron emission tomography (PET) and [carbonyl-(11)C]WAY-100635. Binding potential (
BPP
) was determined using the golden standard of kinetic compartmental modeling using arterial blood samples and radiometabolite determination. Personality traits were assessed using the Karolinska Scales of Personality. We found a strong negative association between serotonin
5-HT1A
receptor
BPP
and neuroticism. That is, individuals with high neuroticism tended to have lower
5-HT1A
receptor binding than individuals with low neuroticism. This finding was confirmed with an independent voxel-based whole-brain analysis. Other personality traits did not correlate with
5-HT1A
receptor
BPP
. Previous observations have reported lower serotonin
5-HT1A
receptor density in major depression. This neurobiological finding may be a trait-like phenomenon and partly explained by higher neuroticism in patients with affective disorders. The link between personality traits and
5-HT1A
receptors should be studied in patients with major depression.
...
PMID:Neuroticism and serotonin 5-HT1A receptors in healthy subjects. 2665 73